SCHEMBL177576

SCHEMBL177576

CC(C)c1[c]nccc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL303322 0.82
SCHEMBL2818903 0.79 TSHR (0.35)
SCHEMBL3525467 0.79
SCHEMBL4679491 0.77
SCHEMBL2565204 0.76
SCHEMBL646821 0.76
SCHEMBL4277857 0.74 CHRNB2 (0.31)
SCHEMBL3526159 0.73
SCHEMBL2067545 0.73 LMNA (0.41)
SCHEMBL18043744 0.73 SLC6A4 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3634975-B1 17-OXIMES OF 15.BETA.-[3-PROPANAMIDO]-SUBSTITUTED ESTRA-1,3,5(10)-TRIEN-17-ONES FOR USE IN INHIBITION OF 17.BETA.-HYDROXYSTEROID DEHYDROGENASES ORGANON R&D FINLAND LTD (FI) 2024-02-28 EP claimed
CN-114206886-B Gold (III) compound, method for preparing the same, and organic light emitting device using the same 广东聚华印刷显示技术有限公司 2024-02-27 CN claimed
CN-110945007-B 15 beta- [ 3-propionylamino ] -substituted estra-1, 3,5 (10) -trien-17-one compounds and 17-oximes thereof for inhibiting 17 beta-hydroxysteroid dehydrogenases 佛恩多制药有限公司 2022-11-18 CN claimed
US-20220127303-A1 THERAPEUTICALLY ACTIVE STEROIDAL DERIVATIVES FORENDO PHARMA LTD (FI) 2022-04-28 US claimed
CN-114206886-A Luminescent gold (III) compound, method for preparing same, and organic light emitting device using same 广东聚华印刷显示技术有限公司 2022-03-18 CN claimed
US-11254703-B2 Therapeutically active steroidal derivatives FORENDO PHARMA LTD (FI) 2022-02-22 US claimed
WO-2021016814-A1 LUMINESCENT GOLD (III) COMPOUND, METHOD FOR PREPARING THE SAME, AND ORGANIC LIGHT-EMITTING DEVICE USING THE SAME GUANGDONG JUHUA PRINTED DISPLAY TECHNOLOGY CO., LTD. (CN) 2021-02-04 WO claimed
US-20200317718-A1 THERAPEUTICALLY ACTIVE STEROIDAL DERIVATIVES FORENDO PHARMA LTD (FI) 2020-10-08 US claimed
US-10717761-B2 Therapeutically active steroidal derivatives FORENDO PHARMA LTD (FI) 2020-07-21 US claimed
EP-3634975-A2 15.BETA.-[3-PROPANAMIDO]-SUBSTITUTED ESTRA-1,3,5(10)-TRIEN-17-ONE COMPOUNDS AND THEIR 17-OXIMES FOR USE IN INHIBITION OF 17.BETA.-HYDROXYSTEROID DEHYDROGENASES Forendo Pharma Ltd (FI) 2020-04-15 EP claimed
US-7371763-B2 Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas BAYER PHARMACEUTICALS CORPORATION (US) 2008-05-13 US claimed
US-20060019990-A1 Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas BAYER HEALTHCARE LLC 2006-01-26 US claimed
JP-2004537511-A 2004-12-16 JP claimed
EP-1379507-A1 HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS Bayer Corporation (US) 2004-01-14 EP claimed
EP-1379505-A2 INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS Bayer Corporation (US) 2004-01-14 EP claimed
US-20030207914-A1 INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS BAYER CORPORATION 2003-11-06 US claimed
WO-2002085859-A1 HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS BAYER CORPORATION (US) 2002-10-31 WO claimed
WO-2002085857-A2 INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS BAYER CORPORATION (US) 2002-10-31 WO claimed
US-20020065296-A1 Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors BAYER CORPORATION 2002-05-30 US claimed
US-5326767-A α-arylacrylates substituted by a heterocyclic radical, and fungicides which contain these compounds BASF AKTIENGESELLSCHAFT (DE) 1994-07-05 US claimed